Current Oncology Reports

, Volume 2, Issue 2, pp 154–156

New developments in lymphoma clinical trials

  • Carol S. Portlock
Clinical Trials Review
  • 19 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    The Non-Hodgkin’s Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997, 89:3909–3918.Google Scholar
  2. 2.
    Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: a progress report. Am J Clin Pathol 1999, 111(suppl 1):S8-S12.PubMedGoogle Scholar
  3. 3.
    Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998, 16:2780–2795.PubMedGoogle Scholar
  4. 4.
    Freedman AS, Neuberg D, Gribben JG, et al.: High-dose chemoradiotherapy and anti-B cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998, 16:13–18.PubMedGoogle Scholar
  5. 5.
    Khouri IS, Ramaguera J, Kantarjian H, et al.: Hyper-CVAD and high dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol 1998, 16:3803–3809.PubMedGoogle Scholar
  6. 6.
    Lister TA, Crowther D, Sutcliff SB, et al.: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989, 7:1630–1636.PubMedGoogle Scholar
  7. 7.
    Cheson D, Horning SJ, Coiffier B, et al.: Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999, 17:1244–1253.PubMedGoogle Scholar
  8. 8.
    Diehl V, Franklin J, Hasenclever D, et al.: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s lymphoma study group. J Clin Oncol 1998, 16:3810–3821.PubMedGoogle Scholar
  9. 9.
    Bartlett NL, Rosenberg SA, Hoppe RT, et al.: Brief chemotherapy, Stanford V and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol 1995, 13:1080–1088.PubMedGoogle Scholar
  10. 10.
    Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478–1484.PubMedCrossRefGoogle Scholar
  11. 11.
    Duggan D, Petroni G, Johnson J, et al.: MOPP/ABV versus ABVD for advanced Hodgkin’s disease—a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC) [abstract]. Proc ASCO 1997, 16:12a.Google Scholar
  12. 12.
    Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998, 339:1506–1514.PubMedCrossRefGoogle Scholar
  13. 13.
    Brice P, Bastian Y, Lepage E, et al.: Comparison in low-tumorburden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe D’Etude des Lymphomes Folliculaires. J Clin Oncol 1997, 15:1110–1117.PubMedGoogle Scholar
  14. 14.
    The International non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993, 329:987–994.CrossRefGoogle Scholar
  15. 15.
    Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993, 328:1002–1006.PubMedCrossRefGoogle Scholar
  16. 16.
    Janicek M, Kaplan W, Neuberg D, et al.: Early restaging gallium scans predict outcome in poor prognosis patients with aggressive non-Hodgkin’s lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997, 15:1631–1637.PubMedGoogle Scholar
  17. 17.
    McLaughlin P, Hagemeister FB, Grillo-Lopez AJ: Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999, 26(suppl 14):79–87.PubMedGoogle Scholar
  18. 18.
    Solal-Celigny P, Lepage E, Brousse N, et al.: Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe de’Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol 1998, 16:2332–2338.PubMedGoogle Scholar
  19. 19.
    Dana BW, Unger J, Fisher RI, et al.: A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to Pro-MACE-MOPP (Day 1–8) [abstract]. Proc ASCO 1998, 17:3a.Google Scholar
  20. 20.
    Rohatiner AZA, Gregory W, Peterson B, et al.: Meta-analysis (MA) of randomized trials evaluating the role of interferon (IFN) as treatment for follicular lymphoma (FL) [abstract]. Proc ASCO 1998, 17:4a.Google Scholar
  21. 21.
    Bendandi M, Gocke CD, Kobrin CB, et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171–1177.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Carol S. Portlock
    • 1
  1. 1.Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations